Using Eplerenone to Prevent Atrial Fibrillation Recurrence in Heart Disease Patients
Potential Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
This study is testing if adding eplerenone to the usual treatment can help people with heart disease and atrial fibrillation avoid having their heart rhythm problems come back.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Asyut) |
| Trial ID | NCT06556732 on ClinicalTrials.gov |
What this trial studies
This prospective comparative study investigates the effectiveness of eplerenone in reducing the recurrence of atrial fibrillation (AF) in patients with structural heart disease. Conducted at the Cardiology Department of Aswan University Hospital, the study involves 100 patients with confirmed AF who are divided into two groups: one receiving eplerenone alongside amiodarone and the other receiving only amiodarone. The primary goal is to assess the recurrence of AF in both groups over the study period.
Who should consider this trial
Good fit: Ideal candidates include patients with non-valvular atrial fibrillation who have undergone cardioversion to sinus rhythm.
Not a fit: Patients with conditions such as rheumatic heart disease, thyroid dysfunction, or significant renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option to reduce AF recurrence in patients with structural heart disease.
How similar studies have performed: While the use of eplerenone in this context is relatively novel, similar studies have shown promise in managing atrial fibrillation with other interventions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously Exclusion Criteria: * Patients with rheumatic heart disease. * Thyroid dysfunction. * Wolf-Parkinson-White (WPW) syndrome. * Renal impairment. * Hyperkalemia. * Acute coronary syndrome. * Pregnancy. * Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%. * On current use of eplerenone.
Where this trial is running
Asyut
- Assiut University Heart Hospital — Asyut, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.